1. Introduction {#s0005}
===============

Next-generation sequencing has allowed for the association of previously unknown genes and pathways with complex human phenotypes. These associations suggest new treatment modalities for previously untreatable rare diseases. Examples are disorders which may benefit from amino acid supplementation.

For example, variants in the gene encoding serine palmitoyltransferase (*SPTLC1*) have been shown to cause both macular telangiectasia type 2 and hereditary sensory and autonomic neuropathy type 1 (HSAN1) or each disorder separately \[[@bb0020]\]. Variants in *SPTLC1* are thought to result in abnormal incorporation of L-alanine or L-glycine instead of [l]{.smallcaps}-serine during sphinganine synthesis, which leads to the accumulation of neurotoxic byproducts, 1-deoxy-sphinganine, 1-deoxymethyl-sphinganine, and 1-deoxy-ceramides or other derivatives. Mouse models of HSAN1 suggested that increases in dietary serine could lead to decreased levels of these neurotoxic byproducts, with similar observations made in a pilot study of oral serine supplementation in individuals with HSAN1 \[[@bb0015],[@bb0025]\]. Thus, there is therapeutic potential for serine supplementation in these rare diseases.

Unfortunately, data regarding the pharmacokinetics of [l]{.smallcaps}-serine are lacking; there is an unmet need for careful observations in individuals taking oral supplementation. Creating accurate models of serine metabolism is challenging as evidenced by the wide range of values that have been reported in the literature \[[@bb0010],[@bb0030]\]. Part of these challenges arise from variability in the endogenous production of serine in the body \[[@bb0030]\].

Here, we report pharmacokinetic values for a female teenage patient with a variant in *SPTLC1* causing a neuromuscular phenotype initiating oral [l]{.smallcaps}-serine supplementation. We provide data for both a single dose, and values of plasma serine measured during a 3-month treatment and dose escalation period. This data may inform the design of future treatments and trials using [l]{.smallcaps}-serine as a supplement.

2. Materials and methods {#s0010}
========================

2.1. Study approval {#s0015}
-------------------

The patient was enrolled in study \#1831 approved by the institutional review board of Seattle Children\'s Hospital.

2.2. Plasma serine measurements {#s0020}
-------------------------------

[l]{.smallcaps}-serine in 500 mg tablets was obtained from Jo Mar Labs (Watsonville, CA). The patient stopped all multivitamins and oral supplements at least 1 week prior to initiation of treatment.

Data for this study is presented over two timepoints. First, pharmacokinetic data is presented for a three-hour sample period prior to the patient beginning regular serine supplementation ([Fig. 1](#f0005){ref-type="fig"}). Treatment was started with 227 mg/kg of serine divided three times per day, or 2 g of serine three times a day. Plasma amino acids were obtained prior to the first 2 g oral dose of serine, then 30, 60, 120, and 180 min after dosing. Amino acids were measured using routine clinical laboratory methods for plasma amino acid quantification using a Biochrom 30+ instrument and ninhydrin detection (Biochrom Ltd., Cambridge, UK).Fig. 1Plasma [l]{.smallcaps}-serine concentration after one oral dose of [l]{.smallcaps}-serine (time 0 min). Data was collected prior to the patient beginning daily supplementation. The patient was fasting prior to and during the sampling.Fig. 1

Second, plasma amino acids were measured at specific intervals prior to and during treatment ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). During this time, the dose of serine was increased slowly to a goal of 400 mg/kg during the second month of treatment.

2.3. Calculation of pharmacokinetic data {#s0025}
----------------------------------------

Non-compartmental analysis of pharmacokinetic parameters was performed using PK Solver 2.0 \[[@bb0040]\]. The terminal elimination rate constant was calculated using three observations in the terminal slope. The AUC calculation method was linear trapezoidal. For calculation of clearance and apparent volume of distribution after oral dosing, a bioavailability of 60% was used based on previously published extraction data \[[@bb0010],[@bb0035]\].

3. Results {#s0030}
==========

Plasma serine concentrations were measured from five blood samples collected over a three-hour period ([Fig. 1](#f0005){ref-type="fig"}). Time 0 is immediately prior to initiation of oral treatment. Pharmacokinetic calculations based on the serine concentrations are shown in [Table 1](#t0005){ref-type="table"}.Table 1Pharmacokinetic data calculated from plasma serine measurements. Definitions: L, liters; h, hours; λ z, terminal elimination rate constant which represents the rate of elimination only; AUC, area under the curve, a measure of systemic exposure of a drug to the body; AUMC, area under the first moment of the plasma concentration-time curve; MRT, the average time a molecule stays in the body; AUC, AUMC, and MRT are calculated for either time zero to 3 h after dose (t~0~-t~3~) or from time zero to infinity (t~0-∞~); CL, clearance, volume of plasma cleared of drug per hour; Vd, volume of distribution, amount of drug in the body divided by the plasma concentration; t~½~, elimination half-life, time it takes for plasma concentration to fall by 50%.Table 1ParameterValueλ z0.47/hAUC t~0~-t~3~778.5 μmol\*h/LAUC t~0-∞~1128 μmol\*h/LAUMC t~0~-t~3~1025 μmol\*h^2^/LAUMC t~0-∞~2819 μmol\*h^2^/LMRT t~0~-t~3~1.3 hMRT t~0-∞~2.5 hCL10.1 L/hVd21.6 Lt~1/2~1.48 h

Plasma serine levels were also measured during a 3-month dose escalation period. Dose was divided three times per day and increased slowly over time from 227 mg/kg to 400 mg/kg. While the timing of the oral dose of serine and blood draws was not controlled, we find that plasma serine levels remained elevated during the observation period. A single low serine value of 170 μmol/L may be due to the timing of supplementation relative to the blood draw ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}).

4. Discussion {#s0035}
=============

Here we report both pharmacokinetic and long-term plasma levels of a patient taking oral [l]{.smallcaps}-serine. Multiple samples obtained at treatment initiation revealed a rapid increase in plasma concentration of serine and corresponding rapid decline. This is consistent with data recently reported by Bosley and colleagues \[[@bb0010]\] who gave 10 study members 20 g of serine for 2 days and observed a similar rapid spike followed by decline in serine levels.

Dosing was based on a study of patients with HSAN1 taking oral [l]{.smallcaps}-serine supplementation at either a low dose of 200 mg/kg or 400 mg/kg \[[@bb0015],[@bb0025]\]. Given the limited data on serine supplementation we began supplementation at 200 mg/kg then slowly increased to a target dose of 400 mg/kg ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). We find that serine levels remained appropriately elevated during the observation period. Serum serine levels at both 200 mg/kg/day and 400 mg/kg/day were similar to those reported by Auranen and colleagues \[[@bb0005]\].

Our pharmacokinetic data revealed an elimination half-life of 1.48 h, similar to the value of 1.45 h reported by Bosley et al. \[[@bb0010]\]. After five half-lives, 97% of steady state is achieved, thus 7.4 h after dose administration only 3% of serine will remain in circulation. From a practical standpoint, this means that optimal oral serine supplementation should be divided in three daily doses.

It is important to keep in mind that the data presented here come from a patient with a genetic disorder that may benefit from serine supplementation. Data from patients with disorders which affect the normal use of serine in the body may give falsely elevated or depressed values. Overall, it is reassuring that our observed elimination half-life is similar to that recently reported for 10 healthy individuals \[[@bb0010]\].

As the number of rare disorders which may benefit from treatment by oral amino acid supplementation increases, the need for additional pharmacokinetic data will increase. Thus, measurements of both healthy individuals and those with a disorder which may benefit from serine supplementation will help to better define the true pharmacokinetics of [l]{.smallcaps}-serine metabolism in humans.

The following is the supplementary data related to this article.Supplementary Table 1Plasma amino acid measurements before and while taking oral [l]{.smallcaps}-serine. Time point "0 days" is prior to the first dose. All other timepoints are in relation to this time. Dose was increased slowly over time from 227 mg/kg to 400 mg/kg. Dose was divided three times per day over the study period. All values are in μmol/L. Values above the reference range are denoted in bold.Supplementary Table 1

Financial support {#s0040}
=================

None.

Declaration of Competing Interest
=================================

None.
